November 9, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
November 4, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 27, 2026
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
October 2, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 4, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 30, 2026
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 7, 2026
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
July 2, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 33